Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Amortization of Deferred Charges (2016 - 2017)

Palisade Bio (PALI) has disclosed Amortization of Deferred Charges for 5 consecutive years, with $12127.0 as the latest value for Q2 2017.

  • On a quarterly basis, Amortization of Deferred Charges fell 15.57% to $12127.0 in Q2 2017 year-over-year; TTM through Dec 2017 was $59781.0, a 82.8% decrease, with the full-year FY2017 number at $59781.0, down 82.8% from a year prior.
  • Amortization of Deferred Charges was $12127.0 for Q2 2017 at Palisade Bio, down from $47654.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $231381.0 in Q4 2013 to a low of $12127.0 in Q2 2017.
  • A 5-year average of $155644.9 and a median of $207350.5 in 2014 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: soared 881.51% in 2014, then plummeted 93.42% in 2016.
  • Palisade Bio's Amortization of Deferred Charges stood at $231381.0 in 2013, then fell by 10.37% to $207388.0 in 2014, then grew by 3.88% to $215440.0 in 2015, then crashed by 70.29% to $63998.0 in 2016, then crashed by 81.05% to $12127.0 in 2017.
  • Per Business Quant, the three most recent readings for PALI's Amortization of Deferred Charges are $12127.0 (Q2 2017), $47654.0 (Q1 2017), and $63998.0 (Q4 2016).